Tokushima University, Tokushima, Japan
Yusuke Arakawa , Mitsuo Shimada , Yuji Morine , Satoru Imura , Tetsuya Ikemoto , Yu Saito , Shinichiro Yamada , Masato Yoshikawa , Katsuki Miyazaki
Background: Several prognostic factors were reported in pancreatic cancer such as neutrophil lymphocyte ratio (NLR), platelet lymphocyte ration (PLR) modified GPS. Fibrinogen platelet ratio (FPR) was reported as one of the prognostic factor of resectable gastric cancer (Surgery today 2019). In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods: Between 2004 and 2019, one hundred and sixty-three patients in our institution with curative resection for pancreatic cancer were enrolled in this retrospective study. The cases of non-curative resection were excluded. The FPR was calculated with the preoperative plasma fibrinogen and the platelet counts. Cut-off value was decided with ROC curve. The patients were divided into high and low FPR group according to cut-off value. Results: The cut-off value of FPR was 25.51. In age, gender, BMI, operative factors including operative type, amount of blood loss and operative time, there was no significant difference between these two groups. Patients in low FPR group had significantly better overall survival (OS) rates and relapse-free survival (RFS) rates compared with high FPR group (p < 0.05). On multivariate analysis, the high FPR, CA19-9 > 300 U/ml and receipt of adjuvant chemotherapy were independent risk factor of post-operative recurrence. Conclusions: The FPR might be a prognostic factor of patients with resectable pancreatic cancer.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2020 ASCO Virtual Scientific Program
First Author: Scott Dawsey
2020 Gastrointestinal Cancers Symposium
First Author: Jessica Allen
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Yuto Kamioka
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kazuki Watabe